A detailed history of Jpmorgan Chase & CO transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 6,018,124 shares of VRTX stock, worth $2.74 Billion. This represents 0.23% of its overall portfolio holdings.

Number of Shares
6,018,124
Previous 5,624,265 7.0%
Holding current value
$2.74 Billion
Previous $2.29 Billion 9.93%
% of portfolio
0.23%
Previous 0.24%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$407.69 - $446.08 $161 Million - $176 Million
393,859 Added 7.0%
6,018,124 $2.52 Billion
Q4 2023

Feb 12, 2024

SELL
$343.0 - $410.68 $165 Million - $198 Million
-481,587 Reduced 7.89%
5,624,265 $2.29 Billion
Q3 2023

Nov 14, 2023

BUY
$338.18 - $362.46 $50.8 Million - $54.5 Million
150,327 Added 2.52%
6,105,852 $2.12 Billion
Q2 2023

Aug 11, 2023

SELL
$314.42 - $351.91 $127 Million - $143 Million
-405,233 Reduced 6.37%
5,955,525 $2.1 Billion
Q1 2023

May 18, 2023

BUY
$283.23 - $323.1 $34.3 Million - $39.1 Million
120,990 Added 1.94%
6,360,758 $2 Billion
Q1 2023

May 11, 2023

BUY
$283.23 - $323.1 $212 Million - $242 Million
749,360 Added 13.65%
6,239,768 $1.97 Billion
Q4 2022

Feb 13, 2023

BUY
$285.76 - $321.48 $180 Million - $203 Million
630,721 Added 12.98%
5,490,408 $1.59 Billion
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $103 Million - $115 Million
-377,855 Reduced 7.21%
4,859,687 $1.41 Billion
Q2 2022

Aug 11, 2022

BUY
$234.96 - $292.55 $99.8 Million - $124 Million
424,873 Added 8.83%
5,237,542 $1.48 Billion
Q1 2022

May 11, 2022

BUY
$221.42 - $260.97 $77.1 Million - $90.9 Million
348,338 Added 7.8%
4,812,669 $1.26 Billion
Q4 2021

Feb 10, 2022

BUY
$177.01 - $223.45 $44.7 Million - $56.4 Million
252,599 Added 6.0%
4,464,331 $980 Million
Q3 2021

Nov 12, 2021

BUY
$181.39 - $202.99 $764 Million - $855 Million
4,211,732 New
4,211,732 $764 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $117B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.